PEOPLE > Carla Greenbaum, M.D.

Carla Greenbaum, M.D.

Director, Benaroya Research Institute Diabetes Program
Director, Benaroya Research Institute Clinical Research Center

Benaroya Research Institute
1201 9th Avenue
Seattle, WA 98101

P: 206-342-6931

F: 206-3426582

E: cjgreen@benaroyaresearch.org

Education and Training

1978 (Undergraduate degree) and 1981 (Medicine)
Brown University
Providence, RI

1987 Endocrinology fellowship
University of Washington
Seattle, WA

Research Interests

Dr. Greenbaum is an international leader in clinical investigations and trials to prevent or intervene in the diabetes autoimmune disease process. She is the vice-chair of Type 1 Diabetes TrialNet, a National Institute of Health (NIH) international network, and principal investigator of the TrialNet Northwest Clinical Center. Diabetes TrialNet conducts clinical trials to stop Type 1 diabetes. Dr. Greenbaum is on the Scientific Review Committee for the Diabetes Vaccine Development Center (Australia), the Clinical Affairs Advisory Committee for the Juvenile Diabetes Research Foundation (JDRF), the Diabetes Group of the NIH sponsored Immune Tolerance Network, as well as serving on other NIH, JDRF, and American Diabetes Association (ADA) editorial and DSMB review committees. She currently serves on the Board of Directors for the Western Washington State ADA and is the Chair of the T1D Exchange Biobank Committee.

SELECTED PUBLICATIONS

Yang J, James EA, Sanda S, Greenbaum C, Kwok WW.  CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring.  Immunology, Mar;138(3):269-79, 2013 [PMID: 23228173] (PMCID:ID: 3573280).

Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; for Diabetes TrialNet and the Immune Tolerance Network:  Rapamycin/IL-2 Combination Therapy in Patients with Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function.  Diabetes, Sep;61(9):2340-8, 2012 [PMID: 22721971] (PMCID: 3425404).

Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM; on behalf of the Type 1 Diabetes TrialNet Study Group.  Fall in C-peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite TrialNet Data.  Diabetes, Aug;61(8):2066-73, 2012 [PMID: 22688329] (PMCID:ID: 3402330).

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; the Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.  The Application of the Diabetes Prevention Trial-Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes.  Diabetes Care, Jul;35(7):1552-5, 2012 (Epub ahead of print) [PMID: 22547092] (PMCID:ID: 3379597).

Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; for the Type 1 Diabetes TrialNet Study Group.  Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies.  Diabetes Care, June;35(6):1213-8, 2012 [PMID: 22446173] (PMCID:ID: 3357246).

Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A: Type 1 Diabetes TrialNet Study Group.  Effect of rituximab on human in vivo antibody immune responses.  J Allergy Clin Immunol, Dec;128(6):1295-1302, 2011 [PMID: 21908031] (NIHMS: 324390).